DBH
Dopamine beta-hydroxylase
Protein Summary
Conversion of dopamine to noradrenaline. The protein encoded by this gene is an oxidoreductase belonging to the copper type II, ascorbate-dependent monooxygenase family. The encoded protein, expressed in neuroscretory vesicles and chromaffin granules of the adrenal medulla, catalyzes the conversion of dopamine to norepinephrine, which functions as both a hormone and as the main neurotransmitter of the sympathetic nervous system. The enzyme encoded by this gene exists exists in both soluble and membrane-bound forms, depending on the absence or presence, respectively, of a signal peptide. Mutations in this gene cause dopamine beta-hydroxylate deficiency in human patients, characterized by deficits in autonomic and cardiovascular function, including hypotension and ptosis. Polymorphisms in this gene may play a role in a variety of psychiatric disorders. [provided by RefSeq, Aug 2017]
- ENST00000393056
- ENSP00000376776
- ENSG00000123454
- DBM
- ORTHYP1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
protein domain | 0.97 | ||
biological process | 0.86 | ||
disease | 0.84 | ||
biological term | 0.83 | ||
molecular function | 0.73 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 1325.63 (req: < 5)
Gene RIFs: 145 (req: <= 3)
Antibodies: 496 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 1325.63 (req: >= 5)
Gene RIFs: 145 (req: > 3)
Antibodies: 496 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 28
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 3
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0